Cognitive improvement demonstrated with Xanamem
Filed with ASX · · 30 pages · English
• Statistically significant results demonstrate cognitive improvement in healthy elderly subjects dosed with 20mg Xanamem daily in the XanaHES dose escalation study • Statistically significant reduction in serum cortisol following treatment with Xanamem 20mg daily • Xanamem 20mg daily continues to exhibit a good safety profile with no serious adverse events observed • Results significantly enhance
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- June 2019 Quarterly Update
- Xanamen Clinical Development & Investor Update
- XanaHES Trial to Continue
- Phase II Alzheimers Disease Trial - results
- March 2019 Quarterly Update
Later from Actinogen Medical
- September 2019 Quarterly Update
- R&D Tax Incentive rebate received of $4.58 million
- ACW 2019 AGM Chairman's Address
- December 2019 Quarterly Update
- Market Update COVID-19
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical